Skip to main content
SpringerLink
Log in

A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Chronic myelogenous leukemia (CML) is a common myeloproliferative disease that is characterized by the clonal expansion of marrow stem cells, and is associated with the Philadelphia chromosome. As the disease progresses, additional chromosome abnormalities may arise. The prognostic impact of secondary chromosomal abnormalities in CML is complex, heterogeneous, and sometimes related to previous treatment. Here, we describe a CML patient in lymphoid blast crisis associated with a new chromosomal abnormality identified, dic(7;12)(p12.21;p12.2) and i(12)(q10) using classical cytogenetics and spectral karyotype analysis. To the best of our knowledge, this is the first report of t(7;12)(p11.1;q11.1) and i(12)(q10) in a CML patient with lymphoid evolution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–22.

    Article  PubMed  CAS  Google Scholar 

  2. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–64.

    Article  PubMed  CAS  Google Scholar 

  3. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.

    Article  PubMed  CAS  Google Scholar 

  4. Hagemeijer A. Chromosomal abnormalities in CML. Baillieres Clin Haematol. 1987;1:963–81.

    Article  PubMed  CAS  Google Scholar 

  5. Zhao L, Khan Z, Hayes L, Glassman A. Interphase fluorescence in situ hybridization analysis: a study using centromeric probes 7, 8 and 12. Ann Clin Lab Sci. 1998;28:51–6.

    PubMed  CAS  Google Scholar 

  6. Ilaria RL Jr. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology Am Soc Hematol Educ Program. 2005;188–94.

  7. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, et al. Randomized comparison of interferon-alpha with bussulphan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84(12):4064–77.

    PubMed  CAS  Google Scholar 

  8. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosom Cancer. 1991;3(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  9. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN (2009): an international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger; 2009.

  10. Wang Y, Hopwood VL, Hu P, Lennon A, Osterberger J, Glassman A. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia. Cancer Genet Cytogenet. 2004;153(1):53–6.

    Article  PubMed  CAS  Google Scholar 

  11. Watmore AE, Potter AM, Sokol RJ, Wood JK. Value of cytogenetic studies in prediction of acute phase CML. Cancer Genet Cytogenet. 1985;14(3–4):293–301.

    Article  PubMed  CAS  Google Scholar 

  12. Swolin B, Weinfeld A, Westin J, Waldenström J, Magnusson B. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet. 1985;18(1):65–79.

    Article  PubMed  CAS  Google Scholar 

  13. Schröck E, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273:494–7.

    Article  PubMed  Google Scholar 

  14. Veldman T, Vignon C, Schrock E, Rowley JD, Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet. 1997;15:406–10.

    Article  PubMed  CAS  Google Scholar 

  15. Oliveira FM, Lucena-Araújo AR, Leite-Cueva SD, Santos GA, Rego EM, Falcão RP. Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. Cancer Genet Cytogenet. 2010;198(1):62–5.

    Article  PubMed  Google Scholar 

  16. Oliveira FM, Falcão RP, de Figueiredo Pontes LL, Simões BP, Tone LG. Insertion (15;14)(q22;q13q32) in a case of Ph+ ALL. Cancer Genet Cytogenet. 2008;185(1):65–7.

    Article  PubMed  Google Scholar 

  17. Johnson E, Cotter FE. Monosomy 7 and 7q associated with myeloid malignancy. Blood Rev. 1997;11:46–55.

    Article  PubMed  CAS  Google Scholar 

  18. Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia. 2001;15:1689–95.

    Article  PubMed  CAS  Google Scholar 

  19. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol. 2005;15:162–74.

    Article  PubMed  CAS  Google Scholar 

  20. Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood. 2000;96(1):358–61.

    PubMed  CAS  Google Scholar 

  21. Boultwood J, Fidler C, Shepherd P, Watkins F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket AJ, Wainscoat JS. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol. 1999;61(1):5–9.

    Article  PubMed  CAS  Google Scholar 

  22. Keller G, Brassat U, Braig M, Heim D, Wege H, Brümmendorf TH. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol Oncol. 2009;27(3):123–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This investigation was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo (Proc. 07/52462-7) and the National Institute of Science and Technology in Stem Cell and Cell Therapy, Ribeirão Preto, Brazil (Proc. 573754/2008-0).

Conflict of interest

There is no conflict of interest. All authors disclose any financial and personal relationships with other people and organizations.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Av. Bandeirantes, 3900, 14049-900, Ribeirão Preto, SP, Brazil

    Fábio Morato de Oliveira, Leonardo de Carvalho Palma, Roberto Passetto Falcão & Belinda Pinto Simões

  2. National Institute of Science and Technology in Stem Cell and Cell Therapy, Ribeirão Preto, Brazil

    Fábio Morato de Oliveira, Leonardo de Carvalho Palma, Roberto Passetto Falcão & Belinda Pinto Simões

Authors
  1. Fábio Morato de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonardo de Carvalho Palma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Passetto Falcão
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Belinda Pinto Simões
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fábio Morato de Oliveira.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Oliveira, F.M., de Carvalho Palma, L., Falcão, R.P. et al. A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia. Med Oncol 29, 2332–2336 (2012). https://doi.org/10.1007/s12032-011-0142-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0142-3

Keywords

Search

Navigation